24 results
Brief Overview of Treatment Agents for COVID-19 - Version 2.01 4/11/2020

#Drugs #Medications #Treatment #COVID19 #Pharmacology #Table
Brief Overview of ... Treatment Agents ... for COVID-19 - ... #COVID19 #Pharmacology ... #Table #Management
Ivermectin. Old anti-parasitic agent making a comeback with recent headlines from in-vitro study that showed antiviral
virus causing COVID ... here is a quick overview ... EmergencyMedicine #Pharmacology ... #Treatment #Virus ... #Antiviral #Management
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
duration same as for treatment ... Disease Note: Treatment ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Recommendations for Preventing ... Infections in HIV-AIDS Preventing ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
Recommendations for Preventing ... Preventing First ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
Recommendations for Preventing ... Infections in HIV-AIDS Preventing ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Toxoplasma gondii Encephalitis in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
Recommendations for Preventing ... #Treatment #opportunistic ... infections #HIVAIDS #management ... #pharmacology # ... pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
for effective treatment ... mucosal #IDSA #Prevention ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Leishmaniasis #Prevention ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Managing Cryptosporidiosis in HIV-AIDS
Preventing Chronic Cryptosporidiosis:
 • Because chronic cryptosporidiosis occurs
Recommendations for Preventing ... Alternative Management ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology